If you are struggling for therapeutic relief from multiple sclerosis, you’ve got a lot of competition…
An new investigational procedure using an old “Gold Standard” technology is causing MS patients to apply in droves for a single site clinical trial. Over 1,000 patients applied for 3o positions at a lone study site in Buffalo, New York in its early trial. And the technology?…Is it a drug or an active agent?…no…it’s “POBA” –> Plain Old Balloon Angioplasty!
The theory of balloon angioplasty’s anticipated success in this new indication for use? This provocative new theory proposes that abnormal blood drainage from the brain may cause or play a role in multiple sclerosis. According to early studies by an Italian vascular specialist, Dr. Paolo Zamboni, who was running out of treatment options for his wife, poor deoxygenated blood drainage caused by twisted, narrowed or blocked cerebrospinal veins may cause “leakage of immune cells into the brain that starts a cascade of inflammatory problems.” In this venous application, balloon angioplasty opens these vessels to increase the volume and rate of drainage…and patients can not wait to receive treatment.
“A lot of people are starting to go to fly-by-night places,” according to Dr. Carlo Tornatore at Washington’s Georgetown University Hospital. “It’s a marathon, not a 100-yard sprint. We have to be very careful.” (Source: Seattle PI, Seattle, WA)
The indication is chronic cerebrospinal venous insufficiency or CCSVI. Further studies of 65 patients by Dr. Zamboni reveal this therapy may be most effective in treating the relapsing-remitting form of MS. But there appears to be a significant relapse rate nearly 50%, similar to that for POBA for coronary arteries in the 1980’s and 1990’s.
Stay tuned…this opens a whole new opportunity for peripheral vascular device manufactures as well as their new MS patients!